Antipsychotic Use During Pregnancy and the Risk of Gestational Diabetes Mellitus A Systematic Review

Basit Öğe Kaydı
dc.contributor.authorUguz, Faruk
dc.date.accessioned2024-02-23T14:21:11Z
dc.date.available2024-02-23T14:21:11Z
dc.date.issued2019
dc.departmentNEÜen_US
dc.description.abstractPurpose This study aimed to review the current literature examining a potential relationship between the use of antipsychotic drugs during pregnancy and gestational diabetes mellitus (GDM). Methods PubMed was searched for English language reports between January 1, 1996, and March 31, 2018, by using combinations of the following key words: antipsychotics, pregnancy, FGAs, SGAs, GDM, obstetric outcomes, pregnancy outcomes, obstetric complications, maternal complications, clozapine, olanzapine, risperidone, aripiprazole, amisulpirde, ziprasidone, quetiapine, haloperidol, chlorpromazine, zuclopenthixol, and flupenthixol. Studies but not case reports, case series, or reviews published in a peer-reviewed journal were eligible for inclusion. Results A total of 10 relevant studies that met the review criteria were examined. Data from these studies indicated that the prevalence rates of GDM in pregnant women using antipsychotic drugs and the nomedication group were 2.6% to 22% and 0.95% to 10.7%, respectively. Most comparative studies reported that antipsychotic treatment during pregnancy was not significantly associated with increased in risk of GDM. In addition, the study results also suggested that underlying maternal psychopathologies might affect the risk of GDM. Implications: Findings from some studies suggesting a higher risk of GDM in pregnant women who were administered antipsychotic drugs were not confirmed by results of many other studies. The current evidence suggests no significant relationship between antipsychotic drugs, including second- and first-generation antipsychotics, and the risk of GDM.en_US
dc.identifier.doi10.1097/JCP.0000000000001002
dc.identifier.endpage167en_US
dc.identifier.issn0271-0749
dc.identifier.issn1533-712X
dc.identifier.issue2en_US
dc.identifier.pmid30624301en_US
dc.identifier.scopus2-s2.0-85062287864en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage162en_US
dc.identifier.urihttps://doi.org/10.1097/JCP.0000000000001002
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13481
dc.identifier.volume39en_US
dc.identifier.wosWOS:000460661500012en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofJournal Of Clinical Psychopharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAntipsychoticsen_US
dc.subjectPregnancyen_US
dc.subjectGestational Diabetes Mellitusen_US
dc.titleAntipsychotic Use During Pregnancy and the Risk of Gestational Diabetes Mellitus A Systematic Reviewen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu